Busilvex Injection
PDF Leaflet Revision Date: 13 August 2008
Clinical Summary
Quick overview from the medicine insert
Indication
Conditioning treatment prior to haematopoietic progenitor cell transplantation.
Dosage (summary)
0.8 mg/kg IV infusion every 6 hours for 4 days.
Special Populations
- Hepatic impairment
- Pregnancy
- Lactation
Pregnancy & Breastfeeding
Contraindicated in pregnancy; breastfeeding should be discontinued during therapy.
Key Drug Interactions
- Itraconazole may reduce busulfan clearance
- Ketobemidone may increase busulfan levels
- Paracetamol may decrease busulfan clearance
Contraindications
- Hypersensitivity to busulfan
- Pregnancy
- Lactation
- Hepatic insufficiency
Common side effects
- Myelosuppression
- Neutropenia
- Thrombocytopenia
- Anaemia
Counselling Points
- Premedicate with anticonvulsants
- Monitor for infections
- Avoid rapid IV injection
Serious warnings
- Profound myelosuppression
- Risk of seizures
- Monitor blood counts frequently
Important Disclaimer
The Busilvex Injection professional information leaflet below is the property of Pierre-Fabre and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
